NCT02261220 is a Phase 1 clinical trial of MEDI4736 in Advanced Solid Tumors, sponsored by MedImmune LLC.

Who is sponsoring NCT02261220?

NCT02261220 is sponsored by MedImmune LLC.

What drugs are being tested in NCT02261220?

Interventions in NCT02261220: MEDI4736, tremelimumab.

What condition does NCT02261220 study?

NCT02261220 studies Advanced Solid Tumors.

Is NCT02261220 still recruiting?

NCT02261220 is currently completed. Last updated 6 March 2020.

Last reviewed 2020-03-06 · How we verify

NCT02261220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Completed Phase 1 Last updated 6 March 2020

What this trial tests

Phase 1 trial testing MEDI4736 in Advanced Solid Tumors in 380 participants. Completed in 27 January 2020.

Timeline

13 October 2014

Primary endpoint
27 January 2020

27 January 2020

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	380
Start date	13 October 2014
Primary completion	27 January 2020
Estimated completion	27 January 2020
Sites	75 locations across France, Netherlands, United Kingdom, Israel, Germany, South Korea, Canada, United States

Drugs / interventions tested

MEDI4736 — full drug profile →
tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

MedImmune LLC — full company profile →

Who can join

Adults 18 to 99, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Powles T, O'Donnell PH, Massard C, Arkenau HT, et al · · 2017 · cited 660× · PMID 28817753 · DOI 10.1001/jamaoncol.2017.2411
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Emerging therapies for small cell lung cancer.
Yang S, Zhang Z, Wang Q. · · 2019 · cited 287× · PMID 31046803 · DOI 10.1186/s13045-019-0736-3
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Zhang Q, Luo J, Wu S, Si H, et al · · 2020 · cited 283× · PMID 32816849 · DOI 10.1158/2159-8290.cd-20-0047
Therapeutic vaccines for high-risk HPV-associated diseases.
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, et al · · 2018 · cited 148× · PMID 29277575 · DOI 10.1016/j.pvr.2017.12.006
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E, Hodi FS. · · 2015 · cited 130× · PMID 26325034 · DOI 10.1172/jci80012
Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
Stadler JC, Belloum Y, Deitert B, Sementsov M, et al · · 2022 · cited 123× · PMID 34815256 · DOI 10.1158/0008-5472.can-21-1718
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC).
Saltos A, Shafique M, Chiappori A. · · 2020 · cited 112× · PMID 32766139 · DOI 10.3389/fonc.2020.01074

Verify or expand the search:

Other trials of MEDI4736

Trials testing the same drug.

NCT02546661 — Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting
NCT02669914 — MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors · Phase 2 · terminated
NCT02868632 — Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer · Phase 1 · withdrawn
NCT02549651 — MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C0 · Phase 1 · completed
NCT02592551 — MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma · Phase 2 · completed

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other MedImmune LLC trials

Trials by the same sponsor.

NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02261220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
Last refreshed: 6 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02261220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing